View Older Stories View More Recent Stories

May 15, 2024 04:05PM Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 7, 2024 08:00AM Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
May 6, 2024 08:00AM Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
Apr 30, 2024 08:00AM Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
Apr 8, 2024 08:00AM Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
Apr 4, 2024 08:01AM Biora Therapeutics (BIOR) Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development
Apr 4, 2024 08:00AM Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Apr 3, 2024 04:05PM Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Apr 1, 2024 08:03AM Biora Therapeutics (BIOR) Announces 5.45M Share Offering at $1.10/sh
Apr 1, 2024 08:00AM Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mar 26, 2024 04:05PM Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Mar 18, 2024 08:00AM Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
Mar 11, 2024 08:00AM Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
Feb 26, 2024 08:00AM Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
Feb 8, 2024 08:00AM Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
Jan 22, 2024 08:00AM Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
Jan 22, 2024 08:00AM Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
Jan 16, 2024 08:00AM Biora Therapeutics Provides Outlook for 2024
Jan 8, 2024 08:00AM Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
Jan 2, 2024 08:00AM Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
Dec 19, 2023 08:00AM Biora Therapeutics (BIOR) Announces New Patent for its NaviCap
Dec 19, 2023 08:00AM Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
Dec 18, 2023 08:02AM Biora Therapeutics (BIOR) Accelerates Debt Reduction and Raises Capital
Dec 18, 2023 08:00AM Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
Dec 11, 2023 08:00AM Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
Nov 30, 2023 04:48PM Biora Therapeutics (BIOR) Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
Nov 30, 2023 04:48PM Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
Nov 13, 2023 04:05PM Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Nov 6, 2023 08:00AM Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
Oct 30, 2023 04:06PM Biora Therapeutics (BIOR) Submits Updated IND Application for BT-600
Oct 30, 2023 04:05PM Biora Therapeutics Submits Updated IND Application for BT-600
Oct 24, 2023 05:52AM Biora Therapeutics (BIOR) to Submit Updated IND Application for BT-600
Oct 23, 2023 05:30PM Biora Therapeutics to Submit Updated IND Application for BT-600
Oct 5, 2023 08:00AM Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
Sep 25, 2023 08:00AM Biora Therapeutics (BIOR) Announces Submission of IND Application to the U.S. FDA for BT-600 Program
Sep 25, 2023 08:00AM Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
Sep 19, 2023 08:04AM Biora Therapeutics (BIOR) Reduces Debt and Largest Shareholder Increases Equity Exposure
Sep 19, 2023 08:00AM Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
Sep 11, 2023 08:01AM Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
Sep 5, 2023 08:03AM Biora Therapeutics (BIOR) Progresses its BioJet Systemic Oral Delivery Platform
Sep 5, 2023 08:00AM Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform
Aug 14, 2023 04:01PM Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Aug 3, 2023 08:01AM Biora Therapeutics (BIOR) Announces New Patents Covering its BioJet Systemic Oral Delivery Platform
Aug 3, 2023 08:00AM Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform
Aug 2, 2023 08:00AM Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference
Jul 27, 2023 08:01AM Biora Therapeutics (BIOR) Announces Clinical Device Performance Study Results for NaviCap
Jul 27, 2023 08:00AM Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform
Jul 27, 2023 08:00AM Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform
Jul 17, 2023 06:00AM Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
Jul 5, 2023 08:03AM Biora Therapeutics (BIOR) Continues to Monetize Legacy Diagnostics Assets
View More Recent Stories View Older Stories